March 8, 2022

Sanjay Keswani, MBBS, FRCP

Dr. Sanjay Keswani is an accomplished physician-scientist with broad R&D expertise in multiple therapeutic areas and is a former neurology faculty member at the Johns Hopkins Hospital as well as an elected Fellow of the Royal College of Physicians, United Kingdom. Dr. Keswani has held senior executive positions in the pharmaceutical industry, including at Roche, where he was Senior Vice President and Global Head of Neuroscience, Ophthalmology and Rare Diseases Research and Early Development, and most recently Annexon Biosciences, where he served as Executive Vice President and Chief Medical Officer. He has been instrumental in the development of multiple approved medicines, including Cymbalta, Aimovig, Emgality, Risdiplam and Faricimab. Dr. Keswani graduated in medicine at St. Bartholomew’s Hospital and holds a First-class Honors degree from St. Mary’s Hospital, London in molecular immunology. He completed his residency in neurology at Johns Hopkins, where he also ran a R01-funded neuroimmunology research lab.

Your browser is out-of-date!

Update your browser to view this website correctly. Outdated Browser